<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04133350</url>
  </required_header>
  <id_info>
    <org_study_id>19P.115</org_study_id>
    <nct_id>NCT04133350</nct_id>
  </id_info>
  <brief_title>Patients With Heart Failure With Preserved Ejection Fraction Adherence to ASV Therapy (PEP ASV)</brief_title>
  <acronym>PEP-ASV</acronym>
  <official_title>Patients With Heart Failure With Preserved Ejection Fraction Adherence to ASV Therapy Pilot Registry (PEP ASV Pilot Registry)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Inova Fairfax Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heart and Diabetes Center North Rhine-Westphalia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CLEMENS HOSPITAL</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Resmed Inc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single-arm, unblinded pilot study and registry that aims to&#xD;
      demonstrate adherence to adaptive servo-ventilation (ASV) therapy in patients with moderate&#xD;
      to severe sleep disordered breathing who have been recently hospitalized. ASV therapy has&#xD;
      been linked to improved outcomes in this population, but adherence to therapy is low. The&#xD;
      AirCurve 10 ASV device that will be used for this study employs newer technologies, such as&#xD;
      web-based monitoring and provides patients feedback, which may increase therapy adherence and&#xD;
      therefore improve patient outcomes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inability to Recruit&#xD;
  </why_stopped>
  <start_date type="Actual">October 16, 2019</start_date>
  <completion_date type="Actual">February 1, 2021</completion_date>
  <primary_completion_date type="Actual">February 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adherence (hours/night)</measure>
    <time_frame>3 months</time_frame>
    <description>Demonstrate acceptable adherence to ASV therapy can be achieved in patients with moderate to severe SDB in a recently hospitalized population of Heart Failure patients with preserved ejection fraction (HFpEF).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Score -</measure>
    <time_frame>3 months</time_frame>
    <description>Quality of life will be assessed using the KCCQ-12, a 12-item validated instrument that measures Quality of Life in heart failure patients on a scale of 0-100. Higher scores indicate higher Quality of Life</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Sleep Disorder; Breathing-Related</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Active Patient Engagement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients are enrolled into the Active Patient Engagement (APE) arm. This arm will receive the APE intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Active Patient Engagement</intervention_name>
    <description>The APE intervention will be delivered through a patient-facing application and website called myAir, which provides patients with access to their own usage data, educational tips, and coaching.</description>
    <arm_group_label>Active Patient Engagement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Patients 18 years or older 2. Patients with heart failure with preserved ejection&#xD;
             fraction (HFpEF; LVEF ≥50%) 3. Hospital admission or equivalent (such as ER visit&#xD;
             alone or clinic visit alone) and acute decompensated HF as determined by:&#xD;
&#xD;
               1. Dyspnea at rest or with minimal exertion AND&#xD;
&#xD;
               2. Treatment with at least one dose of IV diuretic or ultrafiltration AND&#xD;
&#xD;
               3. At least two of the following signs and symptoms:&#xD;
&#xD;
             i. Orthopnea ii. Pulmonary rales that do not clear with cough iii. Congestion on chest&#xD;
             X-ray iv. Local BNP or NT pro-BNP level:&#xD;
&#xD;
          -  No current AFib: BNP≥100 pg/mL or NT pro-BNP≥300 pg/mL OR&#xD;
&#xD;
          -  Current AFib: BNP≥150 pg/mL or NT pro-BNP≥450 pg/mL 4. Sleep disordered breathing&#xD;
             (SDB) documented by screening polygraphy with an AHI≥15 events/hour (e/hr) 5. Patient&#xD;
             is able to fully understand study information and sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Right-sided heart failure without left-sided failure&#xD;
&#xD;
          2. Current chronic use (within 4 weeks of registry entry) of any PAP therapy (e.g., CPAP,&#xD;
             APAP, or bi-level) or contraindicated for PAP therapy&#xD;
&#xD;
          3. Sustained systolic blood pressure &lt;80 mmHg at baseline&#xD;
&#xD;
          4. Complex congenital heart disease&#xD;
&#xD;
          5. Constrictive pericarditis&#xD;
&#xD;
          6. Chronic hypoxemia as evidenced by sustained oxygen saturation ≤ 85% at rest during the&#xD;
             day or at start of nocturnal oximetry recording or regular use of oxygen therapy (day&#xD;
             or night)&#xD;
&#xD;
          7. Transient ischemic attack (TIA) or Stroke within 3 months prior to registry entry&#xD;
&#xD;
          8. Definite clinically evident acute myocardial infarction within 3 months of registry&#xD;
             entry&#xD;
&#xD;
          9. Known amyloidosis, hypertrophic obstructive cardiomyopathy, or arteriovenous fistulas&#xD;
&#xD;
         10. Moderate or greater valvular heart disease as the primary reason for heart failure&#xD;
&#xD;
         11. In the opinion of the investigator, the index acute decompensated HF event was not due&#xD;
             primarily to uncontrolled AFib with fast ventricular response rate&#xD;
&#xD;
         12. Inability to comply with planned study procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INOVA (Inova Heart and Vascular Institute, Inova Fairfax Hospital)</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz- und Diabeteszentrum, Nordrhein-Westfalen</name>
      <address>
        <city>Bad Oeynhausen</city>
        <state>Ruhr-Universität Bochum</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ludgerus Clinic, Department of Cardiology, Clemens Hospital</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 17, 2019</study_first_submitted>
  <study_first_submitted_qc>October 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 21, 2019</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

